Find where to buy products from suppliers in the USA, including: distributors, industrial manufacturers in America, bulk supplies and wholesalers of raw ingredients & finished goods.
Search for products or services, then visit the American suppliers website for prices, SDS or more information. You can also view suppliers in Australia, NZ or the UK.
| Product | Description | |
|---|---|---|
| Protein C from human plasma | Activated, lyophilized powder, ?90% (SDS-PAGE). Group: Fluorescence/luminescence spectroscopy. |  |
| 1,2-Dioleoyl-sn-glycerol | ALN29882 is a glycerolipid located on the plasma membrane. It consists of two fatty acid chains covalently linked to a single glycerol molecule by means of an ester bond. 18:1 DG has been used as a source of diacylglycerol in the diacylglycerol O-acyltransferase 1 (DGAT1) assay. It is also used as a substrate in the DGAT-1 enzyme assay to evaluate compounds as potential inhibitors of DGAT-1. Suitable for lipoprotein overlay screening assays with the recombinant protein His-AtROP6. Uses: Scientific research. Group: Biochemical assay reagents. Alternative Names: sn-1,2-Dioleoylglycerol. CAS No. 24529-88-2. Pack Sizes: 5 mg; 10 mg; 25 mg. Product ID: HY-141572. |  |
| 1,2-Dipalmitoyl-sn-glycero-3-phospho-(1-myoinositol-4-phosphate) | PI(3)P diC16 is a synthetic and purified dipalmitoyl PI(3)P. PI(3)P is enriched in early endosomes having roles in endosome fusion and receptor sorting and internalization in multivesicular bodies. PI(3)P has also been found at the plasma membrane and is involved in the translocation of the glucose transport protein GLUT4. Synonyms: 1,2-dipalmitoyl-sn-glycero-3-phospho-(1'D-myo-inositol-3'-phosphate); PI(3)P diC16; L-alpha-Phosphatidyl-D-myo-inositol 3-monophosphate, dipalmitoyl; D-myo-Inositol, 1-(2R)-2,3-bis(1-oxohexadecyl)oxypropyl hydrogen phosphate 3-(dihydrogen phosphate); Phosphatidylinositol 3-phosphate diC16. Grade: >95%. CAS No. 165689-81-6. Molecular formula: C41H80O16P2. Mole weight: 891.01. |  |
| 2,5-Dioxo-3-sulfo-1-pyrrolidinyl 6-[[5-(hexahydro-2-oxo-1H-thieno[3,4-d]imidazol-4-yl)-1-oxopentyl]amino]hexanoate sodium salt (1:1) | It is a water-soluble, amine-reactive biotinylation reagent designed for labeling proteins, antibodies, and other primary amine-containing molecules. It forms stable amide bonds with primary amines (e.g., lysine residues or N-termini of proteins) via its NHS ester group, enabling irreversible labeling. The reagent is particularly useful for cell-surface protein labeling due to its cell-impermeable properties, making it ideal for plasma membrane protein studies. It is widely used in applications such as protein purification, detection (ELISA, Western blot), and immunoassays. Synonyms: Hexanoic acid, 6-[[5-(hexahydro-2-oxo-1H-thieno[3,4-d]imidazol-4-yl)-1-oxopentyl]amino]-, 2,5-dioxo-3-sulfo-1-pyrrolidinyl ester, sodium salt (1:1); 3-Pyrrolidinesulfonic acid, 1-[[6-[[5-(hexahydro-2-oxo-1H-thieno[3,4-d]imidazol-4-yl)-1-oxopentyl]amino]-1-oxohexyl]oxy]-2,5-dioxo-, monosodium salt; Biotinamidohexanoic acid 3-sulfo-N-hydroxysuccinimide ester sodium salt; 2,5-Dioxo-1-((6-(5-(2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)pentanamido)hexanoyl)oxy)pyrrolidine-3-sulfonate sodium salt. Grade: ≥90%. CAS No. 127062-22-0. Molecular formula: C20H29N4NaO9S2. Mole weight: 556.58. | |
| 7 β-Spironolactone | 7 β-Spironolactone is the 7 β-isomer of Spironolactone. It binds effectively to human plasma proteins. Group: Biochemicals. Alternative Names: (7 β,17α)-7-(Acetylthio)-17-hydroxy-3-oxopregn-4-ene-21-carboxylic Acid γ-Lactone;17-Hydroxy-7 β-mercapto-3-oxo-17α-pregn-4-ene-21-carboxylic Acid γ-Lactone Acetate; 3'-(3-Oxo-7 β-acetylthio-17 β-hydroxyandrost-4-en-17α-yl)-propionic Acid Lactone; 7 β-(Acetylthio)-17α-hydroxy-3-oxopregn-4-ene-21-carboxylic Acid γ-Lactone; SC 11940. Grades: Highly Purified. CAS No. 33784-05-3. Pack Sizes: 1mg. US Biological Life Sciences. |  Worldwide |
| a2-Macroglobulin (human proteinmoiety reduced) (9CI) | a2-Macroglobulin (human proteinmoiety reduced) (9CI). Synonyms: A2M; A-2-M, HUMAN; ALPHA2M; ALPHA2-MACROGLOBIN, HUMAN; ALPHA2-MACROGLOBULIN; ALPHA2-MACROGLOBULIN, HUMAN; ALPHA2-MACROGLOBULIN, HUMAN PLASMA; ALPHA-2 MACROGLOBULIN PLASMA. Grade: 95%. CAS No. 95568-41-5. | |
| Absolute Mag Strong Cation Exchange Silica-coated Magnetic Particles, 1 μm | Absolute Mag Strong Cation Exchange (SCX) Magnetic Beads are uniform, silica-coated superparamagnetic beads specifically designed for quick fractionation of proteins or peptides from complex biological samples (such as serum, plasma, etc.) manually or automatically. The beads allow binding of weaker anions that may not bind strongly enough to Weak Cation Exchange Magnetic Beads, such as Absolute Mag Weak Cation Exchange Magnetic beads. The procedure is quick and simple for sample preparation without the need for laborious repeat pipetting and centrifugation. Uses: Quick fractionation of proteins or peptides from complex biological samples (such as serum, plasma). Pack Sizes: 250 mg. Product ID: WNM-B005. |  |
| Akt1 and Akt2-IN-1 | Akt1 and Akt2-IN-1 is an allosteric inhibitor of Akt1 and Akt2 with the IC50 of 3.5 nM and 42 nM respectively. It has potent and balanced activity. It is dependent on the PH-domain for Akt inhibition. It is selective for Akt1/2 over Akt3 and is highly selective over other members of the AGC family of kinases in vitro. It has potent inhibitory activity against Akt1 and Akt 2 in vivo in a mouse lung and efficacy in a tumor xenograft model. It has moderate activity in an hERG binding assay and is a substrate for human P-glycoprotein. It also shows good physical properties with a human plasma protein binding. Uses: Akt1 and akt2-in-1 has potent inhibitory activity against akt1 and akt 2 and efficacy in a tumor xenograft model. Synonyms: Akt Inhibitor 17; Akti_2008; Akti 2008; Akti2008; Akti-2008; Akt Inhibitor 17; Akt-Inhibitor-17; AktInhibitor17; 3-Phenyl-2-[4-[[4-[5-(2-pyridinyl)-1H-1,2,4-triazol-3-yl]-1-piperidinyl]methyl]phenyl]-1,6-Naphthyridin-5(6H)-one; Akti_2008; 3-phenyl-2-[4-[[4-(3-pyridin-2-yl-1H-1,2,4-triazol-5-yl)piperidin-1-yl]methyl]phenyl]-6H-1,6-naphthyridin-5-one. Grade: >98%. CAS No. 893422-47-4. Molecular formula: C33H29N7O. Mole weight: 539.63. | |
| Albumin | Albumin. CAS No. 9048-49-1. Product ID: PE-0600. Category: Stabilizer; Therapeutic Agents. Product Keywords: Other Materials; Stabilizers; PE-0600; Albumin; Stabilizer; Therapeutic Agents; ; 9048-49-1. Chemical Name: Serum albumin. Grade: Pharmceutical Excipients. Administration route: Intravenous. Dosage Form: Intravenous injection. Stability and Storage Conditions: Albumin is a protein and is therefore prone to chemical degradation and denaturation under extreme pH conditions, high salt concentrations, heat, enzymes, organic solvents and other chemical agents present. Albumin solution should be stored away from light at 2 ~ 25 ° C, or according to label instructions. Source and Preparation: Human blood albumin is a sterile, pyrogen free serum albumin product obtained from a healthy donor's isolate (source blood, plasma, serum or placenta); The source material must not be tested to contain hepatitis B surface antigen. The production process should ensure that the product is safe and can be used for intravenous injection. Applications: Albumin is mainly used as an excipient in the prescription of injectable drugs, as a stabilizer for proteins and enzymes in the prescription. Albumin is also used in the preparation of microspheres and microcapsules in experimental drug delivery systems. As a stabilizer, albumin is used in protein prescriptions at a low concentration of 0.003%. However, concentrations of 1.to 5% are usually |  |
| AM4668 | AM4668 is a potent and selective G-protein coupled receptor 40(GPR40) agonist with EC50 value of 3.6 nM in an IP3 assay in GPR40 transfected A9 cells. It is more potent than AMG 837 and possesses excellent pharmacokinetic properties across species. It could reduce the plasma glucose levels in an OGTT study in human GPR40 knock-in mice. It inhibits insulin secretion from isolated pancreatic islets. Uses: Am4668 could reduce the plasma glucose levels in an ogtt study. it inhibits insulin secretion from isolated pancreatic islets. Synonyms: AM-4668; AM 4668; AM4668 ; (S)-3-(isoxazol-3-yl)-3-(4-((4-methyl-2-(4-(trifluoromethyl)phenyl)thiazol-5-yl)methoxy)phenyl)propanoic acid; (βS)-β-[4-[[4-Methyl-2-[4-(trifluoromethyl)phenyl]-5-thiazolyl]methoxy]phenyl)-3-isoxazolepropanoic acid. Grade: >98 %. CAS No. 1011531-27-3. Molecular formula: C24H19F3N2O4S. Mole weight: 488.48. | |
| Atrial natriuretic factor (1-28) (human, porcine) | Atrial natriuretic factor (1-28) (human, porcine) is a 28 amino acid peptide corresponding to the rat protein sequence. It is an endogenous peptide synthesized in myoendocrine cells of the heart from which it is released into the circulation. It has effects on the renal and cardiovascular systems that decrease vasoconstriction, increase sodium excretion and inhibit renin secretion. It decreases plasma renin activity and cAMP levels in anesthetized rats and increases cGMP levels at 8 μg/kg. It also inhibits arginine vasopressin-induced increase in mean arterial blood pressure in spontaneously hypertensive and control rats when administered intracerebroventricularly at a dose of 150 ng. It produces diuretic, natriuretic and vasodilatory effects through stimulation of guanylate cyclase-linked NPR-A receptors. It plays an important role in blood volume and blood pressure regulation. Synonyms: ANF 1-28; hANF; Atrial Natriuretic Peptide human. CAS No. 91917-63-4. Molecular formula: C127H205N45O39S3. Mole weight: 3080.46. | |
| Atrial Natriuretic Peptide (ANP) (1-28), rat | Atrial natriuretic factor (1-28) (rat) is a 28 amino acid peptide corresponding to the rat protein sequence. It is an endogenous peptide synthesized in myoendocrine cells of the heart from which it is released into the circulation. It has effects on the renal and cardiovascular systems that decrease vasoconstriction, increase sodium excretion and inhibit renin secretion. It decreases plasma renin activity and cAMP levels in anesthetized rats and increases cGMP levels at 8 μg/kg. It also inhibits the arginine vasopressin-induced increase in mean arterial blood pressure in spontaneously hypertensive and control rats when administered intracerebroventricularly at a dose of 150 ng. It produces diuretic, natriuretic and vasodilatory effects through stimulation of guanylate cyclase-linked NPR-A receptors. It plays an important role in blood volume and blood pressure regulation. Uses: Vasodilator agents. Synonyms: Atrial natriuretic factor (1-28) (rat); rANP; Atrial Natriuretic Peptide rat; Cardiodilatin-126; Atrial Natriuretic Factor (1-28) (mouse, rabbit, rat); rANF (1-28); H-Ser-Leu-Arg-Arg-Ser-Ser-Cys(1)-Phe-Gly-Gly-Arg-Ile-Asp-Arg-Ile-Gly-Ala-Gln-Ser-Gly-Leu-Gly-Cys(1)-Asn-Ser-Phe-Arg-Tyr-OH; L-seryl-L-leucyl-L-arginyl-L-arginyl-L-seryl-L-seryl-L-cysteinyl-L-phenylalanyl-glycyl-glycyl-L-arginyl-L-isole. Grade: ≥95%. CAS No. 88898-17-3. Molecular formula: C128H205N45O39S2. Mole weight: 3062 | |
| AZD8055 | A potent, selective, and orally bioavailable ATP-competitive mTOR kinase inhibitor with an IC50 of 0.8 nM. It inhibits the phosphorylation of mTORC1 substrates p70S6K and 4E-BP1 as well as phosphorylation of the mTORC2 substrate AKT and downstream proteins. The rapamycin-resistant T37/46 phosphorylation sites on 4E-BP1 were fully inhibited by AZD8055, resulting in significant inhibition of cap-dependent translation. In vitro, AZD8055 potently inhibits proliferation and induces autophagy in H838 and A549 cells. In vivo, AZD8055 induces a dose-dependent pharmacodynamic effect on phosphorylated S6 and phosphorylated AKT at plasma concentrations leading to tumor growth inhibition. Group: Biochemicals. Alternative Names: 5- [2, 4-Bis [ (3S) -3-methyl-4-morpholinyl] pyrido [2, 3-d] pyrimidin-7-yl] -2-methoxy Benzene methanol; [5-[2,4-Bis((3S)-3-methylmorpholin-4-yl)pyrido[2,3-d]pyrimidin-7-yl]- 2-methoxyphenyl] methanol; AZD 8055; [5- [2, 4-Bis ( (3S) -3-methylmorpholin-4-yl) pyrido [5, 6-e] pyrimidin-7-yl] -2-methoxyphenyl] methanol. Grades: Purified. CAS No. 1009298-09-2. Pack Sizes: 10mg. US Biological Life Sciences. | Worldwide |
| Bikaverin | Antibiotic. Antiprotozoal. Antifungal. Anticancer. ATP synthesis inhibitior. Haemolytic agent. Antioomycete. Spermidine-induced autoactivation inhibitor. Plasma hyaluronan-binding protein (PHBP) inhibitor (active form). Group: Biochemicals. Alternative Names: NSC 215139, BRN 0358013, Lycopersin, Mycogonin, Passiflorin. Grades: Highly Purified. CAS No. 33390-21-5. Pack Sizes: 250ug, 1mg. Molecular Formula: C20H14O8. US Biological Life Sciences. | Worldwide |
| Biotin Phosphatidylinositol 3-phosphate | Biotin Phosphatidylinositol 3-phosphate is a water-soluble analog of PI(3)P labelled with biotin at the sn-1 position. PI(3)P is enriched in early endosomes having roles in endosome fusion and receptor sorting and internalization in multivesicular bodies. PI(3)P has also been found at the plasma membrane and is involved in the translocation of the glucose transport protein GLUT4. Synonyms: Biotin PI(3)P. Grade: >95%. Molecular formula: C37H63N4Na3O19P2S. Mole weight: 1030.90. | |
| Bivalirudin | Bivalirudin is a specific and reversible direct thrombin inhibitor (DTI). It is a synthetic congener of the naturally occurring drug hirudin. It is a DTI that overcomes many limitations seen with indirect thrombin inhibitors, such as heparin. It is a short, synthetic peptide that is potent, highly specific, and a reversible inhibitor of thrombin. It inhibits both circulating and clot-bound thrombin, while also inhibiting thrombin-mediated platelet activation and aggregation. It has a quick onset of action and a short half-life. It does not bind to plasma proteins (other than thrombin) or to red blood cells. Therefore, it has a predictable antithrombotic response. It does not require a binding cofactor such as antithrombin and does not activate platelets. Synonyms: Hirulog; Hirulog I; Angiomax; Hirulog-1; Hirulog1; Hirulog 1; BG8967; BG 8967; BG-8967; LS-172701; LS172701; LS 172701. Grade: > 95%. CAS No. 128270-60-0. Molecular formula: C98H138N24O33. Mole weight: 2180.32. | |
| BLM Helicase Inhibitor, ML216 (ML-216, 1- (4-Fluoro-3- (trifluoromethyl) phenyl) -3- (5- (pyridin-4-yl) -1, 3, 4-thiadiazol-2-yl) urea) | A cell-permeable pyridinyl-thiadiazolylurea compound that selectively blocks Bloom's syndrome protein (BLM) helicase activity of both full-length as well as truncated BLM636-1298 forms (IC50 = 2.98 and 0.97uM, respectively). Competes with and reversibly blocks DNA binding to BLM. However, the inhibition appears to be non-competitive with respect to ATP. Exhibits anti-proliferative activity in cells expressing BLM, but not in those lacking BLM. Induces sister chromatid exchanges (SCEs) and enhances the sensitivity of BLM containing PSNF5 cells to aphidicolin without affecting PSNG13 cells that are devoid of BLM. Displays favorable microsomal (T1/2 > 1.2h) and plasma stability (~100% at 5h). Group: Biochemicals. Grades: Highly Purified. Pack Sizes: 10mg. Molecular Formula: C??H?F?N?OS. US Biological Life Sciences. | Worldwide |
| Bovine factor IX | The zymogen factor IX is a single chain vitamin K-dependent glycoprotein which is synthesized in the liver. The domain structure of factor IX is similar to that of the other vitamin K dependent coagulation factors. The NH2-terminal region contains 12 γ-carboxyglutamic acid (gla) residues which facilitate the calcium dependent binding of factor IX to negatively charged phospholipid surfaces. Two domains which are homologous to epidermal growth factor (EGF) span the region between the NH2-terminal gla domain and the activation peptide (Ala-146 to Arg-180).Factor IX is activated by either factor XIa or the factor VIIa/tissue factor/phospholipid complex. Cleavage at site A (see fig. activates factor X to factor Xa.Human factor IX is prepared from fresh frozen plasma by a combination of conventional procedures and immunoaffinity chromatography. Bovine factor IX is prepared from fresh citrated bovine plasma by a modification of the method described by Fujikawa et al. The purified proteins are supplied in 50% (vol/vol) glycerol/H2O and should be stored at -20°C. Purity is determined by SDS-PAGE analysis and activity is measured using a factor IX clotting assay. Group: Zymogens. CAS No. 9001-28-9. Purity: >95% by SDS-PAGE. Factor IX. Mole weight: 55400. Stability: 12 months. Storage: -20°C. Source: Bovine. Bovine factor IX; Factor IX. Pack: 100 ug. Cat No: CZY-003. |  |
| Bovine Factor X | Factor X is a vitamin K-dependent protein zymogen which is synthesized in the liver and circulates in plasma as a two chain molecule linked by a disulfide bond. Prior to secretion into plasma, post-translational modifications produce 11 gamma-carboxyglutamic acid (gla) residues and a single b-hydroxyaspartic acid residue, which are located within the NH2-terminal light chain. The light chain also contains two epidermal growth factor (EGF) homology domains. The COOH-terminal heavy chain of factor X contains most of the carbohydrate moieties, as well as the latent serine protease domain. The activation of factor X is catalyzed by either the intrinsic factor Xase complex (factor IXa, fa.y of the prothrombinase complex. The first EGF homology domain contains a Ca2+ binding site which acts as a hinge to fold the EGF and GLA domains towards each other. This region of the molecule is involved in the recognition of cellular binding domains.Human factor X is isolated from fresh frozen human plasma by a combination of conventional techniques and immunoaffinity chromatography. In addition to the standard human factor X preparation, Gla-domainless human factor X is also available. Bovine factor X is isolated from fresh bovine plasma using a modification of the procedure reported by Bajaj et al. The purified zymogen is supplied in 50% (vol/vol) glycerol/H2O and should be store. | |
| Bovine Plasminogen | Purified from freshly collected bovine plasma. The protein purity is determined by SDS-PAGE and shows no reduction upon incubation with 2-mercaptoethanol. No Plasmin activity is detected using chromogenic substrate S-2251. Plasminogen is activated to the serine protease plasmin via urokinase, streptokinase or tissue plasminogen activator. Group: Zymogens. Purity: >94% by SDS-PAGE. Plasminogen. Mole weight: 90,000-94,000. Stability: 30 months. Storage: 2-8°C. Source: Bovine. Bovine Plasminogen; Plasminogen. Pack: 1mg. Cat No: CZY-030. | |
| Bovine Protein C | The vitamin K-dependent zymogen, protein C, is synthesized in the liver as a single chain polypeptide and is subsequently converted to a disulfide linked heterodimer, by removal of a dipeptide (Lys-146 and Arg-147) from the precursor molecule. Trace quantities of the single chain form have been observed in plasma. The light chain, which is responsible for the calcium dependent binding of protein C to phospholipid vesicles, contains 11 γ-carboxyglutamic acid (gla) residues, 1 b-hydroxyaspartic acid residue, and 2 epidermal growth factor (EGF) homology domains. The serine protease catalytic triad is located in the heavy chain. Human protein C is susceptible to proteolytic cleavag.g the proteolytic inactivation of factors Va and VIIIa. APC also contributes to the fibrinolytic response by complex formation with plasminogen activator inhibitors.Bovine protein C is prepared from fresh citrated bovine plasma by a modification of the Walker procedure, as described by Haley et al. Human protein C is prepared from fresh frozen citrated human plasma using a combination of immunoaffinity chromatography, and conventional techniques. Protein C is provided in 50% (vol/vol) glycerol/H2O and should be stored at -20°C. Purity is determined by SDS-PAGE analysis and activity is measured using a chromogenic substrate based assay. Group: Zymogens. Purity: >95% by SDS-PAGE. Prote. | |
| Bovine Prothrombin | Prothrombin is a vitamin K-dependent plasma protein which is synthesized in the liver. Prior to secretion into plasma, prothrombin undergoes post-translational modification by a vitamin K-dependent carboxylase which converts ten specific glutamic acid residues to γ-carboxyglutamic acid (gla). The ten gla residues are located within the first 40 amino acids of the mature protein and contribute to the ability of prothrombin to bind to negatively charged phospholipid membranes. Prothrombin contains two regions of internal homology which are referred to as "kringle" structures. These regions of conspicuous secondary structure are located between residues 40 and 270 of the mature p.Ser321 (human) / Arg323-Ser324 (bovine) to a "pro" fragment (fragment 1.2) and thrombin, the latter of which is composed of two chains covalently linked by a disulfide bond. In the case of human prothrombin/thrombin, there is an additional thrombin feed-back cleavage at Arg284-Thr285 resulting in an additional 13 amino acids being removed from the mature thrombin A chain.Human prothrombin is prepared from fresh frozen human plasma as described by Bajaj and coworkers. Bovine prothrombin is prepared from fresh bovine plasma using a modification of the procedure described by Owen and coworkers. Purified prothrombin is supplied in 50% (vol/vol) glycerol/H2O and should be stored at -20. | |
| Cabazitaxel | Cabazitaxel increases CYP3A enzyme activities in rat hepatocytes. The mean ex-vivo human plasma protein binding of Cabazitaxel is 91.6%. Synonyms: XRP6258; XRP-6258; XRP 6258; TXD 258; TXD-258; TXD258; RPR116258A; axoid XRP6258; dimethoxydocetaxel US brand name: Jevtana. Grade: >98%. CAS No. 183133-96-2. Molecular formula: C45H57NO14. Mole weight: 835.93. | |
| Cephaloridine | It is produced by the strain of Semisynthetic first generation cephalosporin for injection. Cephaloridine had the same antibacterial spectrum as Cephalothin, but had stronger antibacterial effect than Cephalothin. Oral malabsorption, The drug is excreted 75%-80% in the urine by injection for 24h. The half-life of normal plasma elimination was 1.5h, and the binding rate of plasma protein was 22%. Synonyms: cefaloridine; Cefaloridin; Cephaloridin; Cephaloridinum; Cefalorizin; Cephalomycine; N-(7-((2-Thienyl)acetamido)ceph-3-em-3-ylmethyl)pyridinium-4-carboxylate; 7-((2-Thienyl)acetamido)-3-(1-pyridylmethyl)cephalosporanic acid. Grade: 95%. CAS No. 50-59-9. Molecular formula: C19H17N3O4S2. Mole weight: 415.48. | |
| Chelerythrine chloride | Cell permeable potent inhibitor of protein kinase C. Does not inhibit tyrosine protein kinases, cAMP-dependent protein kinase or calcium/calmodulin-dependent protein kinase. Antiplatelet, anti-inflammatory, antibacterial and antitumor compound. Apoptosis inducer in cancer cells in vitro and in vivo. Activates MAPK and JUNK signaling pathways. Affects translocation of PKC from cytosol to plasma membrane. Neurite outgrowth stimulator. Inhibits binding of BclXL to Bak (IC50 =1.5uM) or Bad proteins and stimulates apoptosis in several cancer cell lines. Blocks human P2X7 receptor. Induces cell cycle arrest in G1 phase. Specific cyclooxygenase-2 inhibitor. Group: Biochemicals. Alternative Names: NSC 36405, 1,2-Dimethoxy-N-methyl-[1,3]benzodioxolo[5,6-c]phenanthridinium chloride. Grades: Highly Purified. CAS No. 3895-92-9. Pack Sizes: 1mg, 5mg, 25mg. Molecular Formula: C21H18ClNO4. US Biological Life Sciences. | Worldwide |
| Cholesterol | Cholesterol is the major sterol in mammals. It is making up 20-25% of structural component of the plasma membrane. Plasma membranes are highly permeable to water but relatively impermeable to ions and protons. Cholesterol plays an important role in determining the fluidity and permeability characteristics of the membrane as well as the function of both the transporters and signaling proteins [1] [2]. Cholesterol is also an endogenous estrogen-related receptor α (ERRα) agonist [3]. Uses: Scientific research. Group: Natural products. CAS No. 57-88-5. Pack Sizes: 10 mM * 1 mL; 500 mg. Product ID: HY-N0322. | |
| Cholesterol-13C2 | Cholesterol- 13 C 2 is the 13 C labeled Cholesterol. Cholesterol is the major sterol in mammals. It is making up 20-25% of structural component of the plasma membrane. Plasma membranes are highly permeable to water but relatively impermeable to ions and protons. Cholesterol plays an important role in determining the fluidity and permeability characteristics of the membrane as well as the function of both the transporters and signaling proteins [1] [2]. Cholesterol is also an endogenous estrogen-related receptor α (ERRα) agonist [3]. Uses: Scientific research. Group: Isotope-labeled compounds. CAS No. 78887-48-6. Pack Sizes: 1 mg; 5 mg. Product ID: HY-N0322S5. | |
| Cholesterol-d6 | Cholesterol-d 6 is the deuterium labeled Cholesterol. Cholesterol is the major sterol in mammals. It is making up 20-25% of structural component of the plasma membrane. Plasma membranes are highly permeable to water but relatively impermeable to ions and protons. Cholesterol plays an important role in determining the fluidity and permeability characteristics of the membrane as well as the function of both the transporters and signaling proteins [1] [2]. Cholesterol is also an endogenous estrogen-related receptor α (ERRα) agonist [3] [4]. Uses: Scientific research. Group: Isotope-labeled compounds. CAS No. 60816-17-3. Pack Sizes: 1 mg; 5 mg. Product ID: HY-N0322S1. | |
| Cholesterol-d7 | Cholesterol-d 7 is the deuterium labeled Cholesterol. Cholesterol is the major sterol in mammals. It is making up 20-25% of structural component of the plasma membrane. Plasma membranes are highly permeable to water but relatively impermeable to ions and protons. Cholesterol plays an important role in determining the fluidity and permeability characteristics of the membrane as well as the function of both the transporters and signaling proteins [1] [2]. Cholesterol is also an endogenous estrogen-related receptor α (ERRα) agonist [3]. Uses: Scientific research. Group: Isotope-labeled compounds. CAS No. 83199-47-7. Pack Sizes: 1 mg; 5 mg; 10 mg. Product ID: HY-N0322S. | |
| Cholesterol (Standard) | Cholesterol (Standard) is the analytical standard of Cholesterol. This product is intended for research and analytical applications. Cholesterol is the major sterol in mammals. It is making up 20-25% of structural component of the plasma membrane. Plasma membranes are highly permeable to water but relatively impermeable to ions and protons. Cholesterol plays an important role in determining the fluidity and permeability characteristics of the membrane as well as the function of both the transporters and signaling proteins [1] [2]. Cholesterol is also an endogenous estrogen-related receptor α (ERRα) agonist [3]. Uses: Scientific research. Group: Natural products. CAS No. 57-88-5. Pack Sizes: 25 mg; 50 mg; 100 mg. Product ID: HY-N0322R. | |
| Cholesterol (Water Soluble) | Cholesterol Water Soluble is a major sterol in mammals, constituting 20-25% of the structural composition of the plasma membrane. The plasma membrane is highly permeable to water but relatively impermeable to ions and protons. Cholesterol Water Soluble plays an important role in determining the fluidity and permeability characteristics of membranes and the function of transporters and signaling proteins. Cholesterol Water Soluble is also an endogenous estrogen-related receptor alpha (ERR?) agonist. Cholesterol Water Soluble can be used to study the effects of cholesterol on potassium currents in inner hair cells[1][2]. Uses: Scientific research. Group: Natural products. Pack Sizes: 25 mg; 50 mg. Product ID: HY-N0322A. | |
| CLP257 | CLP257 is a selective K+-Cl cotransporter KCC2 activator with an EC50 of 616 nM. CLP257 is inactive against NKCC1, GABAA receptors, KCC1, KCC3 or KCC4. CLP257 restores impaired Cl transport in neurons with diminished KCC2 activity. CLP257 alleviates hypersensitivity in rats with neuropathic pain. CLP257 modulates plasmalemmal KCC2 protein turnover post-translationally[1][2]. Uses: Scientific research. Group: Signaling pathways. CAS No. 1181081-71-9. Pack Sizes: 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-110143. | |
| Coagulation Factor Calibrator Plasma | The Coagulation Factor Calibrator Plasma is a lyophilized reference plasma intended for use in the calibration of Antigen assays for factor II, factor VII, factor X, factor XI, factor XIII, Protein C, Protein S, Antithrombin III, von Willebrand Factor and fibrinogen by ELISA. It is prepared from a pool of normal citrated human plasma collected from a minimum of 20 donors, buffered with HEPES and stabilizers and lyophilized. Group: Biologicals. Pack Sizes: 1ml. US Biological Life Sciences. | Worldwide |
| coagulation factor Xa | A blood coagulation factor formed from the proenzyme factor X by limited proteolysis. Factor X is a glycoprotein composed of a heavy chain and a light chain, which are generated from a precursor protein by the excision of the tripeptide RKR and held together by one or more disulfide bonds. The activated factor Xa converts prothrombin to thrombin in the presence of factor Va, Ca2+ and phospholipids. Scutelarin (EC 3.4.21.60) has similar specificity, but does not require factor Va. Group: Enzymes. Synonyms: thrombokinase; prothrombase; prothrombinase; activated blood-coagulation factor X; autoprothrombin C; thromboplastin; plasma thromboplastin; factor Xa; activated Stuart-Prower factor; activated factor X. Enzyme Commission Number: EC 3.4.21.6. CAS No. 9002-5-5. Factor Xa. Storage: Store it at +4 ?C for short term. For long term storage, store it at -20 ?C?-80 ?C. Form: Liquid or lyophilized powder. EXWM-4150; coagulation factor Xa; EC 3.4.21.6; 9002-05-5; thrombokinase; prothrombase; prothrombinase; activated blood-coagulation factor X; autoprothrombin C; thromboplastin; plasma thromboplastin; factor Xa; activated Stuart-Prower factor; activated factor X. Cat No: EXWM-4150. | |
| CP-346086 | CP-346086 is a potent and orally active microsomal triglyceride transfer protein (MTP) inhibitor, with an IC50 of 2.0 nM for human and rodent MTP. CP-346086 can lower plasma cholesterol and triglycerides in vivo[1]. Uses: Scientific research. Group: Signaling pathways. CAS No. 186390-48-7. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-113955. | |
| Curcumin-d6 | Labeled Curcumin. A natural phenolic compound. Potent anti-tumor agent having anti-inflammatory and anti-oxidant properties. Induces apoptosis in cancer cells and inhibits phorbol ester-induced protein kinase C (PKC) activity. Reported to inhibit production of inflammatory cytokines by peripheral blood monocytes and alveolar macrophages. Potent inhibitor of EGFR tyrosine kinase and IκB kinase. Inhibits inducible nitric oxide synthase (iNOS), cycloxygenase and lipoxygenase. Easily penetrates into the cytoplasm of cells, accumulating in membranous structures such as plasma membrane, endoplasmic reticulum and nuclear envelope. Group: Biochemicals. Alternative Names: (1E,6E)-1,7-Bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione-d6; (E,E)-1,7-Bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione-d6; C Yellow 15-d6; C.I. 75300-d6; Curcuma-d6; Curcumine-d6; Diferuloylmethane-d6; Haidr-d6; Halad-d6; Haldar-d6; Ukon-d6. Grades: Highly Purified. CAS No. 1246833-26-0. Pack Sizes: 5mg. Molecular Formula: C21H14D6O6, Molecular Weight: 374.42. US Biological Life Sciences. | Worldwide |
| Dalcetrapib | Dalcetrapib (JTT-705) is an orally active cholesteryl ester transfer protein (CETP) inhibitor with IC 50 s of 204.6 nM and 6 μM against recombinant human (rh) CETP and human plasma CETP, respectively [1] [2]. Uses: Scientific research. Group: Signaling pathways. Alternative Names: JTT-705; RO4607381. CAS No. 211513-37-0. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg; 250 mg. Product ID: HY-14950. | |
| Dimethyl-l-arginine | Dimethyl-l-arginine is naturally found in blood plasma. It is produced from the continual protein modification processes in the cytoplasm of all human cells. Uses: Enzyme inhibitors. Synonyms: N,N-dimethylarginine; ADMA; Asymmetric dimethylarginine; NG,NG-dimethyl-L-arginine. Grade: 97%. CAS No. 30315-93-6. Molecular formula: C8H18N4O2. Mole weight: 202.258. | |
| dipeptidyl-peptidase IV | A homodimer. An integral protein of the plasma membrane of lymphocytes and other mammalian cells, in peptidase family S9 (prolyl oligopeptidase family). The reaction is similar to that of the unrelated EC 3.4.14.11 Xaa-Pro dipeptidyl-peptidase of lactococci. Group: Enzymes. Synonyms: dipeptidyl aminopeptidase IV; Xaa-Pro-dipeptidyl-aminopeptidase; Gly-Pro naphthylamidase; postproline dipeptidyl aminopeptidase IV; lymphocyte antigen CD26; glycoprotein GP110; dipeptidyl peptidase IV; glycylproline aminopeptidase; glycylproline aminopeptida. Enzyme Commission Number: EC 3.4.14.5. CAS No. 54249-88-6. DPP IV. Storage: Store it at +4 ?C for short term. For long term storage, store it at -20 ?C?-80 ?C. Form: Liquid or lyophilized powder. EXWM-4050; dipeptidyl-peptidase IV; EC 3.4.14.5; 54249-88-6; dipeptidyl aminopeptidase IV; Xaa-Pro-dipeptidyl-aminopeptidase; Gly-Pro naphthylamidase; postproline dipeptidyl aminopeptidase IV; lymphocyte antigen CD26; glycoprotein GP110; dipeptidyl peptidase IV; glycylproline aminopeptidase; glycylproline aminopeptidase; X-prolyl dipeptidyl aminopeptidase; pep X; leukocyte antigen CD26; glycylprolyl dipeptidylaminopeptidase; dipeptidyl-peptide hydrolase; glycylprolyl aminopeptidase; dipeptidyl-aminopeptidase IV; DPP IV/CD26; amino acyl-prolyl dipeptidyl aminopeptidase; T cell triggering molecule Tp103; X-PDAP. Cat No: EXWM-4050. | |
| Di-(tert-Butyl-dimethylsilyl) Curcumin | Protected Curcumin. A natural phenolic compound. Potent anti-tumor agent having anti-inflammatory and anti-oxidant properties. Induces apoptosis in cancer cells and inhibits phorbol ester-induced protein kinase C (PKC) activity. Reported to inhibit production of inflammatory cytokines by peripheral blood monocytes and alveolar macrophages. Potent inhibitor of EGFR tyrosine kinase and IκB kinase. Inhibits inducible nitric oxide synthase (iNOS), cycloxygenase and lipoxygenase. Easily penetrates into the cytoplasm of cells, accumulating in membranous structures such as plasma membrane, endoplasmic reticulum and nuclear envelope. Group: Biochemicals. Alternative Names: (1E, 4Z, 6E) -1, 7-Bis[4-[[ (1, 1-dimethylethyl) dimethylsilyl]oxy]-3-methoxyphenyl]-5-hydroxy-1, 4, 6-heptatrien-3-one. Grades: Highly Purified. CAS No. 1134639-23-8. Pack Sizes: 25mg. US Biological Life Sciences. | Worldwide |
| Doxycycline | It is produced by the strain of Oxytetracycline or Methacycline. It is regarded as the third generation of tetracycline. It shows broad spectrum antibacterial and antiprotozoan activity and acts by binding to the 30S and 50S ribosomal subunits, blocking protein synthesis. Its antibacterial spectrum is similar to Tetracycline, its antibacterial activity is 2-8 times of Tetracycline, its plasma elimination half-life is as long as 18-22h, and it has little effect on renal function. Synonyms: 6-Deoxy-5-hydroxytetracycline; 6-Deoxyoxytetracycline; Doxytetracycline; Hydramycin; Medeomycin; Vibramycin; Doxycyclinum; Monodox; Oracea; Doxy-Caps; Vibravenos; 5-Hydroxy-alpha-6-deoxytetracycline; 6-alpha-Deoxy-5-oxytetracycline. Grade: >98% by HPLC. CAS No. 564-25-0. Molecular formula: C22H24N2O8. Mole weight: 444.44. | |
| Doxycycline hydrochloride | It is produced by the strain of Oxytetracycline or Methacycline. It is regarded as the third generation of tetracycline. It shows broad spectrum antibacterial and antiprotozoan activity and acts by binding to the 30S and 50S ribosomal subunits, blocking protein synthesis. Its antibacterial spectrum is similar to Tetracycline, its antibacterial activity is 2-8 times of Tetracycline, its plasma elimination half-life is as long as 18-22h, and it has little effect on renal function. It can be used for the prevention and treatment of domestic animal respiratory diseases and mixed infection of bacterial diseases when respiratory diseases occur. Uses: Anti-bacterial agents. Synonyms: Doxylin; samecin; 6-deoxy-5-oxytetracycline hydrochloride; novadox; liomycin; retens; Doxycycline HCl; tecacin; mespafin; Doxigalumicina; Doxylin; Deoxy-5-hydroxytetracycline hydrochloride. Grade: >98%. CAS No. 10592-13-9. Molecular formula: C22H25ClN2O8. Mole weight: 480.89. | |
| Elacridar | Elacridar hydrochloride (GF120918A) is a P-glycoprotein inhibitor, and has been used both in vitro and in vivo as a tool inhibitor of P-glycoprotein (Pgp) to investigate the role of transporters in the disposition of various test molecules. In vitro, GF120918A demonstrated high plasma protein binding across species, although a definitive protein binding evaluation was precluded by poor recovery, particularly in buffer and in mouse, rat, and dog plasma. GF120918A did not demonstrate potent inhibition of several human cytochrome P450 enzymes evaluated in vitro, with IC(50) values well above concentrations anticipated to be achieved in vivo. Together, these data confirm the utility of GF120918A as a tool P-glycoprotein inhibitor in preclinical species and offer additional guidance on preclinical dose regimens likely to produce P-glycoprotein-mediated effects. Synonyms: GF120918; GF-120918; GF 120918; GF-120918A; GF120918A; GF 120918A; GG 918; D03968. Elacridar hydrochloride. CAS No. 143664-11-3. Molecular formula: C34H33N3O5. Mole weight: 563.654. | |
| Elotuzumab | Elotuzumab is a monoclonal antibody used in the treatment of multiple myeloma, a type of cancer that affects plasma cells in the bone marrow. It targets the SLAMF7 (Signaling Lymphocytic Activation Molecule Family member 7) protein found on the surface of myeloma cells and natural killer cells. Elotuzumab is typically used in combination with other drugs, such as lenalidomide and dexamethasone, to increase its effectiveness. It is administered via intravenous infusion and is used in patients who have received prior therapies for multiple myeloma. Synonyms: Elotuzumab (anti-SLAMF7); Immunoglobulin G1, anti-(human protein CS1) (human-mouse HuLuc63 heavy chain), disulfide with human-mouse HuLuc63 κ-chain, dimer; BMS 901608; Empliciti; HuLuc 63; PDL 063. CAS No. 915296-00-3. | |
| ent-Ezetimibe | The lipid-lowering drug, the first and only cholesterol absorption inhibitor, effectively reduces intestinal cholesterol absorption and lowers plasma cholesterol levels as well as hepatic cholesterol stores through selective inhibition of small intestinal cholesterol transporter proteins. Alternative Names: (3S,4R)-1-(4-Fluorophenyl)-3-((R)-3-(4-fluorophenyl)-3-hydroxypropyl)-4-(4-hydroxyphenyl)azetidin-2-one. FST3D70Q0D. (3S,4R)-1-(4-FLUOROPHENYL)-3-[(3R)-3-(4-FLUOROPHENYL)-3-HYDROXYPROPYL]-4-(4-HYDROXYPHENYL)AZETIDIN-2-ONE. CAS No. 1376614-99-1. Product ID: API1376614991. Molecular formula: C24H21F2NO3. Mole weight: 409.4. SMILES: C1=CC(=CC=C1C2C(C(=O)N2C3=CC=C(C=C3)F)CCC(C4=CC=C(C=C4)F)O)O. Standard: USP/BP/EP. Category: Lipid-Lowering APIs. |  |
| ES9-17 | ES9-17 is an analog of ES9 (endosidin9), which is an inhibitor of clathrin heavy chain (CHC). ES9-17 is an inhibitor of clathrin-mediated endocytosis (CME), a major route for internalization of plasma membrane proteins and molecules from the extracellular environment in plants. ES9-17 inhibits the uptake of transferrin and FM4-64. ES9-17 also inhibits root growth of Arabidopsis seedings[1][2]. Uses: Scientific research. Group: Signaling pathways. CAS No. 55854-43-8. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-131683. | |
| Evacetrapib | Evacetrapib is a potent and selective of CETP inhibitor, which inhibits human recombinant CETP protein ( IC 50 5.5 nM) and CETP activity in human plasma ( IC 50 36 nM) in vitro. Uses: Scientific research. Group: Signaling pathways. Alternative Names: LY2484595. CAS No. 1186486-62-3. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-13327. | |
| Evinacumab | Evinacumab (REGN1500) is a human anti- ANGPTL3 ( angiopoietin-like protein 3 ) monoclonal antibody (IgG4 class antibody). Evinacumab reduces plasma lipids in dyslipidemic mice by blocking ANGPTL3. Evinacumab can be used in studies of homozygous familial hypercholesterolaemia (HoFH), refractory hypercholesterolaemia (both familial and non-familial) and severe hypertriglyceridaemia [1]. Uses: Scientific research. Group: Inhibitory antibodies. Alternative Names: REGN1500. CAS No. 1446419-85-7. Pack Sizes: 1 mg; 5 mg. Product ID: HY-P99194. | |
| Fenoprofen | Fenoprofen, a non-steroidal anti-inflammatory drug, acts as an anti-inflammatory analgesic and antipyretic highly bound to plasma proteins. Synonyms: Benzeneacetic acid, α-methyl-3-phenoxy-; Hydratropic acid, m-phenoxy-; α-Methyl-3-phenoxybenzeneacetic acid; (±)-2-(3-Phenoxyphenyl)propionic acid; (±)-Fenoprofen; (±)-m-Phenoxyhydratropic acid; 2-(3-Phenoxyphenyl)-1-propanoic acid; 2-(3-Phenoxyphenyl)propionic acid; 2-(m-Phenoxyphenyl)propionic acid; 3-Phenoxyhydratropic acid; dl-2-(3-Phenoxyphenyl)propionic acid; Lilly 53858; m-Phenoxyhydratropic acid. Grade: ≥96%. CAS No. 29679-58-1. Molecular formula: C15H14O3. Mole weight: 242.28. | |
| Fenoprofen acyl-β-D-glucuronide | Fenoprofen acyl-β-D-glucuronide is a metabolite of Fenoprofen. Fenoprofen is a non-steroidal anti-inflammatory drug that acts as an anti-inflammatory analgesic and antipyretic highly bound to plasma proteins. Synonyms: Fenoprofen glucuronide; β-D-Glucopyranuronic acid, 1-(α-methyl-3-phenoxybenzeneacetate); Fenoprofen Acyl Glucuronide; (2S,3S,4S,5R,6S)-3,4,5-Trihydroxy-6-((2-(2-phenoxyphenyl)propanoyl)oxy)tetrahydro-2H-pyran-2-carboxylic acid; 1-(α-Methyl-3-phenoxybenzeneacetate) β-glucopyranuronic acid. Grade: ≥98%. CAS No. 35440-36-9. Molecular formula: C21H22O9. Mole weight: 418.39. | |
| ferroxidase | The enzyme in blood plasma (ceruloplasmin) belongs to the family of multicopper oxidases. In humans it accounts for 95% of plasma copper. It oxidizes Fe(II) to Fe(III), which allows the subsequent incorporation of the latter into proteins such as apotransferrin and lactoferrin. An enzyme from iron oxidizing bacterium strain TI-1 contains heme a. Group: Enzymes. Synonyms: ceruloplasmin; caeruloplasmin; ferroxidase I; iron oxidase; iron(II):oxygen oxidoreductase; ferro:O2 oxidoreductase; iron II:oxygen oxidoreductase; hephaestin; HEPH. Enzyme Commission Number: EC 1.16.3.1. CAS No. 9031-37-2, 104404-69-5. Storage: Store it at +4 ?C for short term. For long term storage, store it at -20 ?C?-80 ?C. Form: Liquid or lyophilized powder. EXWM-1075; ferroxidase; EC 1.16.3.1; 9031-37-2, 104404-69-5; ceruloplasmin; caeruloplasmin; ferroxidase I; iron oxidase; iron(II):oxygen oxidoreductase; ferro:O2 oxidoreductase; iron II:oxygen oxidoreductase; hephaestin; HEPH. Cat No: EXWM-1075. | |
| FITC-LC-TAT (47-57) | This fluorescent (FITC)-labeled TAT peptide contains a long chain (LC) to prevent FITC from degradation. Abs/Em = 493/522 nm. TAT is the most characteristic fragment of HIV trans-activator protein (TAT). The arginine-rich TAT peptide penetrates the plasma membrane directly rather than through endocytosis. Synonyms: FITC-LC-Tyr-Gly-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg-NH2. Grade: >95%. | |
| FTI-277 | FTI-277, a peptide mimetic of the COOH-terminal Cys-Val-Ile-Met of K-Ras4B that inhibited potently FTase in vitro (IC50 = 500 pM) and was highly selective for FTase over geranylgeranyltransferase I (GGTase I) (IC50 = 50 nM). FTI-277, the methyl ester derivative of FTI-276, was extremely potent (IC50 = 100 nM) at inhibiting H-Ras, but not the geranylgeranylated Rap1A processing in whole cells. Treatment of H-Ras oncogene-transformed NIH 3T3 cells with FTI-277 blocked recruitment to the plasma membrane and subsequent activation of the serine/threonine kinase c-Raf-1 in cells transformed by farnesylated Ras (H-RasF), but not geranylgeranylated, Ras (H-RasGG). FTI-277 induced accumulation of cytoplasmic non-farnesylated H-Ras that was able to bind Raf and form cytoplasmic Ras/Raf complexes in which Raf kinase was not activated. Furthermore, FTI-277 blocked constitutive activation of mitogen-activated protein kinase (MAPK) in H-RasF, but not H-RasGG, or Raf-transformed cells. FTI-277 also inhibited oncogenic K-Ras4B processing and constitutive activation of MAPK, but the concentrations required were 100-fold higher than those needed for H-Ras inhibition. The results demonstrate that FTI-277 blocks Ras oncogenic signaling by accumulating inactive Ras/Raf complexes in the cytoplasm, hence preventing constitutive activation of the MAPK cascade. Uses: Radiation-sensitizing agents. Synonyms: FTI-277; FTI 277; FTI277. CAS No. 170006-73-2. M | |
| Gabexate Mesylate | Gabexate Mesylate is a serine protease inhibitor. Gabexate Mesylate inhibits trypsin, plasmin, plasma kallikrein and thrombin. Gabexate Mesylate inhibits lipopolysaccharide-induced tumor necrosis factor-α (TNF-α) production through nuclear factor-κB and activator protein-1 activation. Group: Biochemicals. Alternative Names: 4-[[6-[ (Aminoiminomethyl) amino]-1-oxohexyl]oxy]benzoic Acid Ethyl Ester Monomethanesulfonate; Arodate; FOY; FOY 007; FOY-S 983; Gabexate Mesilate; Gabexate Monomethanesulfonate; Megacert; Mesyl Gabexate. Grades: Highly Purified. CAS No. 56974-61-9. Pack Sizes: 10mg. US Biological Life Sciences. | Worldwide |
| GIRK Activator, ML297 (1-(3,4-Difluorophenyl)-3-(3-methyl-1-phenyl-1H-pyrazol-5-yl)urea, N-(3,4-Difluorophenyl)-N?-(3-methyl-1-phenyl-1H-pyrazol-5-yl)urea, CID 56642816, VU0456810) | A blood-brain barrier-permeable, non-toxic phenyl-pyrazolylurea compound that acts as a direct, potent, fast, and reversible activator of GIRK1 (G-protein activated inward-rectifying K+ channel containing subunit 1) containing channels (EC50 = 162, 914, and 887nM in Thallium influx assay for GIRK1/2, GIRK1/3, and GIRK1/4 expressed in HEK-293 cell lines). Its action does not require the presence of an activated Gi GPCR. Shown to be inactive towards GIRK2, GIRK2/3, Kir2.1, KV7.4 and GABAA, and weakly active against a panel of 61 other receptors, ion channels, enzymes, transporters, and proteins even at higher concentration (~10uM). Exhibits desirable pharmacokinetic properties with good solubility (17.5uM), predicted hepatic clearance (88 ml/min/kg), and Tmax of 640nM and 130nM in plasma and brain, respectively. Shown to reduce locomotor function and seizure frequency in electroshock- and chemically-induced murine epilepsy models (60mg/kg, i.p). Group: Biochemicals. Grades: Highly Purified. CAS No. 1443246-62-5. Pack Sizes: 10mg. Molecular Formula: C??H??F?N?O. US Biological Life Sciences. | Worldwide |
| GloPIPs Biotin-PI(3)P | GloPIPs Biotin-PI(3)P is labelled at the sn-1 position with BODIPY®-FL (505/513), BODIPY®-TMR (544/574), or biotin. The sn-1 linkage in these labelled PIPs has been changed to a more stable amide from an ester. PI(3)P is enriched in early endosomes having roles in endosome fusion and receptor sorting and internalization in multivesicular bodies. PI(3)P has also been found at the plasma membrane and is involved in the translocation of the glucose transport protein GLUT4. Grade: >95%. Molecular formula: C31H53N4Na3O17P2S. Mole weight: 916.75. | |
| glycosylphosphatidylinositol phospholipase D | This enzyme is also active when O-4 of the glucosamine is substituted by carrying the oligosaccharide that can link a protein to the structure. It therefore cleaves proteins from the lipid part of the glycosylphosphatidylinositol (GPI) anchors, but does so by hydrolysis, whereas glycosylphosphatidylinositol diacylglycerol-lyase (EC 4.6.1.14) does so by elimination. It acts on plasma membranes only after solubilization of the substrate with detergents or solvents, but it may act on intracellular membranes. Group: Enzymes. Synonyms: GPI-PLD; glycoprotein phospholipase D; phosphatidylinositol phospholipase D; phosphatidylinositol-specific phospholipase D. Enzyme Commission Number: EC 3.1.4.50. CAS No. 113756-14-2. Storage: Store it at +4 ?C for short term. For long term storage, store it at -20 ?C?-80 ?C. Form: Liquid or lyophilized powder. EXWM-3733; glycosylphosphatidylinositol phospholipase D; EC 3.1.4.50; 113756-14-2; GPI-PLD; glycoprotein phospholipase D; phosphatidylinositol phospholipase D; phosphatidylinositol-specific phospholipase D. Cat No: EXWM-3733. | |
| HL-60 Electroporation Kit | Electroporation buffer optimized for HL60 Plasmacytoma Cells. Optimized electroporation protocol provided for transfection of si/miRNA, DNA, mRNA, and small proteins. Feature high transfection efficacy and cell viability. Uses: Electroporation of DNA, RNA, protein and small molecules. Product ID: 1752. |  Nevada, Texas, USA |
| Human Coagulation Factor VII | Human factor VII is a single chain, vitamin K-dependent, plasma glycoprotein which is synthesized in the liver. Prior to secretion into the blood, post translational modification by a vitamin K-dependent carboxylase produces ten-carboxyglutamic acid (gla) residues located in the NH2-terminal portion of the molecule, which facilitate cell membrane binding. Factor VII is proteolytically activated to the serine protease, factor VIIa, during coagulation. Factor VII can be activated by thrombin, factor IXa, factor Xa or factor XIIa. The activation results in cleavage of the single chain molecule on the COOH-terminal side of arginine-152, to produce an NH2-terminal derived light chai.nzyme complex catalyzes the conversion of both factor IX to factor IXa and factor X to factor Xa. The cDNA for factor VII has been isolated and the nucleotide sequence determined. Factor VII shares extensive sequence homology with other serine proteases including factor IX, factor X and protein C.Human factor VII is purified using a combination of conventional techniques and immunoaffinity chromatography. The purified protein is supplied in 50% (vol/vol) glycerol/H2O and should be stored at -20°C. Purity is determined by SDS-PAGE analysis and activity is measured in a factor VII clotting assay. Group: Zymogens. CAS No. 9001-25-6. Purity: >95% by SDS-PAGE. Factor VII. Mole weigh. | |
| Human Factor IX | The zymogen factor IX is a single chain vitamin K-dependent glycoprotein which is synthesized in the liver. The domain structure of factor IX is similar to that of the other vitamin K dependent coagulation factors. The NH2-terminal region contains 12 γ-carboxyglutamic acid (gla) residues which facilitate the calcium dependent binding of factor IX to negatively charged phospholipid surfaces. Two domains which are homologous to epidermal growth factor (EGF) span the region between the NH2-terminal gla domain and the activation peptide (Ala-146 to Arg-180).Factor IX is activated by either factor XIa or the factor VIIa/tissue factor/phospholipid complex. Cleavage at site A (see fig.lly activates factor X to factor Xa.Human factor IX is prepared from fresh frozen plasma by a combination of conventional procedures and immunoaffinity chromatography. Bovine factor IX is prepared from fresh citrated bovine plasma by a modification of the method described by Fujikawa et al. The purified proteins are supplied in 50% (vol/vol) glycerol/H2O and should be stored at -20°C. Purity is determined by SDS-PAGE analysis and activity is measured using a factor IX clotting assay. Group: Zymogens. CAS No. 9001-28-9. Purity: >95% by SDS-PAGE. Factor IX. Mole weight: 55000. Stability: 12 months. Storage: -20°C. Source: Human. Human Factor IX; Factor IX. Pack: 100 ug. Cat No: CZY-002. | |
| Human Factor X | Factor X is a vitamin K-dependent protein zymogen which is synthesized in the liver and circulates in plasma as a two chain molecule linked by a disulfide bond. Prior to secretion into plasma, post-translational modifications produce 11 gamma-carboxyglutamic acid (gla) residues and a single b-hydroxyaspartic acid residue, which are located within the NH2-terminal light chain. The light chain also contains two epidermal growth factor (EGF) homology domains. The COOH-terminal heavy chain of factor X contains most of the carbohydrate moieties, as well as the latent serine protease domain. The activation of factor X is catalyzed by either the intrinsic factor Xase complex (factor IXa, fac.y of the prothrombinase complex. The first EGF homology domain contains a Ca2+ binding site which acts as a hinge to fold the EGF and GLA domains towards each other. This region of the molecule is involved in the recognition of cellular binding domains.Human factor X is isolated from fresh frozen human plasma by a combination of conventional techniques and immunoaffinity chromatography. In addition to the standard human factor X preparation, Gla-domainless human factor X is also available. Bovine factor X is isolated from fresh bovine plasma using a modification of the procedure reported by Bajaj et al. The purified zymogen is supplied in 50% (vol/vol) glycerol/H2O and should be store. | |
| Human Factor XI | Factor XI is a plasma glycoprotein which circulates in a non-covalent complex with high molecular weight kininogen. The mature molecule is synthesized in the liver and is a two-chain homodimer with a molecular weight of approximately 160,000. It is estimated that 5% of the total mass is attributable to carbohydrate. The two identical monomers have molecular weights of 80,000, and are joined together by disulfide bonds. Thus by SDS-PAGE analysis, factor XI appears as a single band both non-reduced (Mr=160,000), and reduced (Mr=80,000).Factor XI circulates as a zymogen and requires proteolytic activation to acquire serine protease activity. The conversion of factor XI to factor XIa is.activity or antigen levels. This latter observation may be related to the ability of the tissue factor/factor VIIa complex to also activate factor IX to IXa.Historically, factor XI has been difficult to purify due to its relatively low concentration in plasma, and its susceptibility to proteolysis. Factor XI is purified from fresh frozen plasma that is stabilized by added inhibitors. The plasma is first treated with BaCl2 to remove the vitamin K-dependent proteins, and factor XI is then isolated by affinity chromatography. A final chromatography step on heparin sepharose yields a homogeneous preparation of intact factor XI. The finished product is supplied in 50% (vol/vol) glycerol/H2. | |
| Human Factor XIII | Factor XIII is the zymogenic form of the glutaminyl-peptide g-glutamyl transferase factor XIIIa (fibrinoligase, plasma transglutaminase, fibrin stabilizing factor, E.C. 2.3.2.13). Factor XIII is unique among transamidases in that it is a zymogen in vivo. Factor XIII is found both extracellularly in plasma and intracellularly in platelets, megakaryocytes, monocytes, placenta, uterus, liver and prostrate tissues. Plasma factor XIII is synthesized in the liver and circulates as a tetramer (Mr=320,000), composed of 2 pairs of nonidentical subunits (A2B2). The intra-cellular forms are synthesized in the tissues where they reside as dimers (Mr=146,000) of 2 identical A chains (A2). The A.nly after the Ca2+ (Kd=10-3M) and fibrin(ogen) (Kd=10-8M) dependent dissociation of the B subunit dimer from the A2' dimer.In the coagulation cascade, factor XIIIa functions to stabilize the fibrin clot by crosslinking the a and g-chains of fibrin. Other proteins known to be substrates for Factor XIIIa which may be hemostatically important include fibronectin, α2-antiplasmin, collagen, factor V, von Willebrand Factor and thrombospondin.Factor XIII is purified from fresh frozen human plasma by a modification of the procedures described by Folke and Lorand involving barium citrate, ammonium sulfate and glycine precipitations, ion exchange chromatography and gel filtration. Factor. | |
| Human gla-domainless Factor X | Factor X is a vitamin K-dependent protein zymogen which is synthesized in the liver and circulates in plasma as a two chain molecule linked by a disulfide bond. Prior to secretion into plasma, post-translational modifications produce 11 gamma-carboxyglutamic acid (gla) residues and a single b-hydroxyaspartic acid residue, which are located within the NH2-terminal light chain. The light chain also contains two epidermal growth factor (EGF) homology domains. The COOH-terminal heavy chain of factor X contains most of the carbohydrate moieties, as well as the latent serine protease domain. The activation of factor X is catalyzed by either the intrinsic factor Xase complex (factor.e prothrombinase complex. The first EGF homology domain contains a Ca2+ binding site which acts as a hinge to fold the EGF and GLA domains towards each other. This region of the molecule is involved in the recognition of cellular binding domains.Human factor X is isolated from fresh frozen human plasma by a combination of conventional techniques and immunoaffinity chromatography. In addition to the standard human factor X preparation, Gla-domainless human factor X is also available. Bovine factor X is isolated from fresh bovine plasma using a modification of the procedure reported by Bajaj et al. The purified zymogen is supplied in 50% (vol/vol) glycerol/H2O and should be store. | |
| Human Prethrombin-1 | Prothrombin is a vitamin K-dependent plasma protein which is synthesized in the liver. Prior to secretion into plasma, prothrombin undergoes post-translational modification by a vitamin K-dependent carboxylase which converts ten specific glutamic acid residues to γ-carboxyglutamic acid (gla). The ten gla residues are located within the first 40 amino acids of the mature protein and contribute to the ability of prothrombin to bind to negatively charged phospholipid membranes. Prothrombin contains two regions of internal homology which are referred to as "kringle" structures. These regions of conspicuous secondary structure are located between residues 40 and 270 of the mature.Ser321 (human) / Arg323-Ser324 (bovine) to a "pro" fragment (fragment 1.2) and thrombin, the latter of which is composed of two chains covalently linked by a disulfide bond. In the case of human prothrombin/thrombin, there is an additional thrombin feed-back cleavage at Arg284-Thr285 resulting in an additional 13 amino acids being removed from the mature thrombin A chain.Human prothrombin is prepared from fresh frozen human plasma as described by Bajaj and coworkers. Bovine prothrombin is prepared from fresh bovine plasma using a modification of the procedure described by Owen and coworkers. Purified prothrombin is supplied in 50% (vol/vol) glycerol/H2O and should be stored at -20. | |
| Human Prethrombin-2 | Prothrombin is a vitamin K-dependent plasma protein which is synthesized in the liver. Prior to secretion into plasma, prothrombin undergoes post-translational modification by a vitamin K-dependent carboxylase which converts ten specific glutamic acid residues to γ-carboxyglutamic acid (gla). The ten gla residues are located within the first 40 amino acids of the mature protein and contribute to the ability of prothrombin to bind to negatively charged phospholipid membranes. Prothrombin contains two regions of internal homology which are referred to as "kringle" structures. These regions of conspicuous secondary structure are located between residues 40 and 270 of the mature.Ser321 (human) / Arg323-Ser324 (bovine) to a "pro" fragment (fragment 1.2) and thrombin, the latter of which is composed of two chains covalently linked by a disulfide bond. In the case of human prothrombin/thrombin, there is an additional thrombin feed-back cleavage at Arg284-Thr285 resulting in an additional 13 amino acids being removed from the mature thrombin A chain.Human prothrombin is prepared from fresh frozen human plasma as described by Bajaj and coworkers. Bovine prothrombin is prepared from fresh bovine plasma using a modification of the procedure described by Owen and coworkers. Purified prothrombin is supplied in 50% (vol/vol) glycerol/H2O and should be stored at -20. | |
| Human Protein C | The vitamin K-dependent zymogen, protein C, is synthesized in the liver as a single chain polypeptide and is subsequently converted to a disulfide linked heterodimer, by removal of a dipeptide (Lys-146 and Arg-147) from the precursor molecule. Trace quantities of the single chain form have been observed in plasma. The light chain, which is responsible for the calcium dependent binding of protein C to phospholipid vesicles, contains 11 γ-carboxyglutamic acid (gla) residues, 1 b-hydroxyaspartic acid residue, and 2 epidermal growth factor (EGF) homology domains. The serine protease catalytic triad is located in the heavy chain. Human protein C is susceptible to proteolytic cleavag.ng the proteolytic inactivation of factors Va and VIIIa. APC also contributes to the fibrinolytic response by complex formation with plasminogen activator inhibitors.Bovine protein C is prepared from fresh citrated bovine plasma by a modification of the Walker procedure, as described by Haley et al. Human protein C is prepared from fresh frozen citrated human plasma using a combination of immunoaffinity chromatography, and conventional techniques. Protein C is provided in 50% (vol/vol) glycerol/H2O and should be stored at -20°C. Purity is determined by SDS-PAGE analysis and activity is measured using a chromogenic substrate based assay. Group: Zymogens. CAS No. 42617-41-4. Purity: >95. | |
| Human Prothrombin | Prothrombin is a vitamin K-dependent plasma protein which is synthesized in the liver. Prior to secretion into plasma, prothrombin undergoes post-translational modification by a vitamin K-dependent carboxylase which converts ten specific glutamic acid residues to γ-carboxyglutamic acid (gla). The ten gla residues are located within the first 40 amino acids of the mature protein and contribute to the ability of prothrombin to bind to negatively charged phospholipid membranes. Prothrombin contains two regions of internal homology which are referred to as "kringle" structures. These regions of conspicuous secondary structure are located between residues 40 and 270 of the mature p.-Ser321 (human) / Arg323-Ser324 (bovine) to a "pro" fragment (fragment 1.2) and thrombin, the latter of which is composed of two chains covalently linked by a disulfide bond. In the case of human prothrombin/thrombin, there is an additional thrombin feed-back cleavage at Arg284-Thr285 resulting in an additional 13 amino acids being removed from the mature thrombin A chain.Human prothrombin is prepared from fresh frozen human plasma as described by Bajaj and coworkers. Bovine prothrombin is prepared from fresh bovine plasma using a modification of the procedure described by Owen and coworkers. Purified prothrombin is supplied in 50% (vol/vol) glycerol/H2O and should be stored at -20. | |
| Human Prothrombin Fragment 1 | Prothrombin is a vitamin K-dependent plasma protein which is synthesized in the liver. Prior to secretion into plasma, prothrombin undergoes post-translational modification by a vitamin K-dependent carboxylase which converts ten specific glutamic acid residues to γ-carboxyglutamic acid (gla). The ten gla residues are located within the first 40 amino acids of the mature protein and contribute to the ability of prothrombin to bind to negatively charged phospholipid membranes. Prothrombin contains two regions of internal homology which are referred to as "kringle" structures. These regions of conspicuous secondary structure are located between residues 40 and 270 of the mat.1 (human) / Arg323-Ser324 (bovine) to a "pro" fragment (fragment 1.2) and thrombin, the latter of which is composed of two chains covalently linked by a disulfide bond. In the case of human prothrombin/thrombin, there is an additional thrombin feed-back cleavage at Arg284-Thr285 resulting in an additional 13 amino acids being removed from the mature thrombin A chain.Human prothrombin is prepared from fresh frozen human plasma as described by Bajaj and coworkers. Bovine prothrombin is prepared from fresh bovine plasma using a modification of the procedure described by Owen and coworkers. Purified prothrombin is supplied in 50% (vol/vol) glycerol/H2O and should be stored at -20. | |
| Human Prothrombin Fragment 1.2 | Prothrombin is a vitamin K-dependent plasma protein which is synthesized in the liver. Prior to secretion into plasma, prothrombin undergoes post-translational modification by a vitamin K-dependent carboxylase which converts ten specific glutamic acid residues to γ-carboxyglutamic acid (gla). The ten gla residues are located within the first 40 amino acids of the mature protein and contribute to the ability of prothrombin to bind to negatively charged phospholipid membranes. Prothrombin contains two regions of internal homology which are referred to as "kringle" structures. These regions of conspicuous secondary structure are located between residues 40 and 270 of the ma. (human) / Arg323-Ser324 (bovine) to a "pro" fragment (fragment 1.2) and thrombin, the latter of which is composed of two chains covalently linked by a disulfide bond. In the case of human prothrombin/thrombin, there is an additional thrombin feed-back cleavage at Arg284-Thr285 resulting in an additional 13 amino acids being removed from the mature thrombin A chain.Human prothrombin is prepared from fresh frozen human plasma as described by Bajaj and coworkers. Bovine prothrombin is prepared from fresh bovine plasma using a modification of the procedure described by Owen and coworkers. Purified prothrombin is supplied in 50% (vol/vol) glycerol/H2O and should be stored at -20. | |
Our database is helping our users find suppliers everyday.
